
|Videos|July 9, 2021
Implications of Phase 3 Trial Results Assessing Efficacy, Safety of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained the implications of the trial results on the treatment opportunities available for this patient population.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
The Weekly Dose: Cyclosporiasis Outbreak Grows, AI-Powered Refills Pilot, and New FDA Approvals in Alzheimer Disease
3
Brain Imaging Study Links Long COVID to Dopamine Neuron Injury, Pointing to Repurposed Treatments
4
GLP-1s and Oncology: The Drug Interaction Clinicians Aren't Talking About
5







































































































